Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Share News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 380.00
Bid: 374.00
Ask: 386.00
Change: 0.00 (0.00%)
Spread: 12.00 (3.209%)
Open: 380.00
High: 380.00
Low: 380.00
Prev. Close: 380.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MaxCyte flags 2022 revenue growth, sets new guidance

Tue, 07th Mar 2023 09:32

(Sharecast News) - Cell engineering technology company MaxCyte said in an update on Tuesday that it was expecting full-year 2022 total revenue of $44.3m, which would represent growth of 31% over 2021.

The AIM-traded firm said its fourth quarter total revenue was expected to total $12.4m, making for year-on-year growth of 22%.

It said its installed base at the end of 2022 was higher than 600 instruments, compared to over 500 instruments at the end of the prior year.

The company's total SPL partnerships of 18 at year-end, including three added in 2022 itself, were described as "instrumental" in driving growth.

In January, MaxCyte announced an additional SPL partnership with Catamaran Bio, which it said would further expand the company's market reach.

MaxCyte laid out its initial 2023 guidance for total revenue growth of between 21% and 26% over 2022, including core revenue growth of 20% to 25%, and SPL programme-related revenue of around $6m.

"We delivered strong growth across the business in 2022, giving us confidence as reflected in our initial 2023 revenue guidance," said president and chief executive officer Doug Doerfler.

"Our diverse and robust partnership portfolio continues to grow with three new partnerships added in 2022, in addition to the signing of a partnership with Vertex Pharmaceuticals following the transfer from CRISPR Therapeutics for the development of its CRISPR/Cas9-based gene-edited therapy.

"We look forward to further expansion of our partnerships based on a strong pipeline and the continued progression of our partners' programs as they move into and through the clinic towards commercialisation."

At 1100 GMT, shares in MaxCyte were flat at 390p.

Reporting by Josh White for Sharecast.com.

More News
21 Apr 2020 16:59

MaxCyte Annual Loss Widens As Carma Investment Increases

MaxCyte Annual Loss Widens As Carma Investment Increases

Read more
9 Apr 2020 14:54

UK TRADING UPDATE SUMMARY: Naked Wines, Distil Get Bar-Closure Boost

UK TRADING UPDATE SUMMARY: Naked Wines, Distil Get Bar-Closure Boost

Read more
21 Feb 2020 11:53

MaxCyte to consolidate stock to single trading line

(Sharecast News) - Life sciences company MaxCyte announced the consolidation of its two lines of common stock into a single unrestricted line of common stock on Friday.

Read more
20 Jan 2020 10:58

MaxCyte 'exceptionally positive' following strong FY trading performance

(Sharecast News) - Clinical-stage life sciences company MaxCyte told investors on Monday that its board was "exceptionally positive" of the group's future following a stellar year.

Read more
20 Jan 2020 09:00

MaxCyte Shares Rise As It Expects To Report 30% Increase In Revenue

MaxCyte Shares Rise As It Expects To Report 30% Increase In Revenue

Read more
4 Dec 2019 16:14

MaxCyte inks new development agreement with KSQ Therapeutics

(Sharecast News) - Cell-based therapeutics and life sciences company MaxCyte has entered into a new development and commercialisation agreement with its existing partner KSQ Therapeutics, it announced on Wednesday.

Read more
4 Dec 2019 11:50

MaxCyte Shares Rise As It Signs Development Deal With KSQ Therapeutics

MaxCyte Shares Rise As It Signs Development Deal With KSQ Therapeutics

Read more
21 Nov 2019 18:55

MaxCyte Inks Non-Exclusive Licence Agreement With Vor Biopharma

MaxCyte Inks Non-Exclusive Licence Agreement With Vor Biopharma

Read more
21 Nov 2019 16:40

MaxCyte strikes deal with oncology company Vor Biopharma

(Sharecast News) - Cell-based therapies and life sciences company MaxCyte announced a clinical and commercial licence agreement with oncology company Vor Biopharma on Thursday, under which Vor would use MaxCyte's 'Flow Electroporation' technology to produce engineered hematopoietic stem cells (eHSCs), and initiate investigational new drug-enabling studies to accelerate its progress towards the clinic.

Read more
24 Oct 2019 12:53

MaxCyte Advances Phase I Clinical Trial Of Cancer Drug MCY-M11

MaxCyte Advances Phase I Clinical Trial Of Cancer Drug MCY-M11

Read more
7 Oct 2019 12:23

MaxCyte And Editas Ink Five Medicine Licence Deal, EDIT-301 Included

MaxCyte And Editas Ink Five Medicine Licence Deal, EDIT-301 Included

Read more
18 Sep 2019 11:59

MaxCyte Interim Rises Revenue But Loss Widens On CARMA Investment

(Alliance News) - Life sciences company MaxCyte Inc on Wednesday reported first half revenue growth but its loss widened as expenses soared.In the six months to June 30, the firm's rose

Read more
11 Sep 2019 16:04

UK Earnings, Trading Statements Calendar - Next 7 Days

Thursday 12 September WM Morrison SupermarketsHalf Year ResultsBrooks MacdonaldFull Year

Read more
17 Jul 2019 13:43

MaxCyte Progresses On MCY-M11 Development As Interim Revenue Rises

(Alliance News) - MaxCyte Inc on Wednesday reported double-digit revenue growth in the first half of 2019 and expects to see continued progress throughout the second half of the year.The is

Read more
26 May 2019 21:53

Sunday share tips: IQE, MaxCyte

(Sharecast News) - In his 'Inside the City' column for The Sunday Times, Ben Woods looked at the effect of Donald Trump's posturing against Huawei on the chipmaking industry - particularly, wafer semiconductor technology minnow IQE.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.